Retina Today Journal Club moderator Richard Kaiser, MD, invited Tamer Mahmoud, MD, PhD, to review his study on a novel approach to submacular hemorrhage. In the area of anti-VEGF therapy, visual outcomes are now typically good in cases of age-related macular degeneration, except in the case of a sub retinal hemorrhage.
Dr. Mahmoud accidentally discovered a new technique for treating submacular hemorrhage that includes injecting tissue plasmin activator, bevacizumab (Avastin, Genentech), and an air bubble into the subretinal space, resulting in a superior response by the air bubble covering the submacular space. The results of the pilot study showed that the technique resulted in patients' visual acuity returning to baseline; however, a formal prospective study is needed to further evaluate this novel procedure.
read: RETINA TODAY JUNE 2015